OasisLMS

ACMG Fall 2026 Seminar Series

Wednesdays, October 7, November 4, and December 2 | 11:00 am ET – 12:30 pm ET

Total 4.5 AMA PRA Category 1 Credits™ and P.A.C.E.^®

Credit Claiming by December 31, 2026

Genomic medicine is evolving rapidly, driven by breakthroughs in therapeutics, advances in diagnosis, and expanding access to genetic services. The ACMG Fall 2026 Seminar Series is designed for medical geneticists, laboratory geneticists, genetic counselors, trainees, and the broader genetics team, following that arc across three sessions. The series brings evolving trends in genomic medicine into a new forum between the 2026 and 2027 Annual Clinical Genetics Meetings, keeping the field's most timely conversations going year-round, including:

• October 7, 2026: Session 1: Novel and Emerging Therapeutics
• November 4, 2026: Session 2: Smarter Diagnosis
• December 2, 2026: Session 3: Cancer, Equity, and Global Access

Each session is held virtually on the first Wednesday of the month, October through December 2026, 11:00 AM to 12:30 PM ET, running approximately 90 minutes across two ~45-minute presentations followed by discussion. Should you miss one of the sessions, you will be able to review it until December 31, 2026 for educational credits.

This series delivers practical, current updates across the frontiers of genomic medicine, from gene therapy, and expanding skeletal dysplasia treatments to clinical use of the human pangenome, genomic reanalysis, integrated cancer risk assessment, and genomic testing in low- and middle-income settings. Together, the three sessions aim to equip the genetics team to translate emerging therapeutics, diagnostics, and equity-focused approaches into real-world patient care.

Session Descriptions:

October 7, 2026 — Session 1: Novel and Emerging Therapeutics. This session examines how genomic medicine is moving from supportive care to targeted, disease-modifying treatment. Presentations will review the rapidly expanding therapeutic landscape for skeletal dysplasias, and address the collaboration required to secure patient access to newly approved rare-disease therapies.

November 4, 2026 — Session 2: Smarter Diagnosis. This session focuses on translating emerging tools into everyday laboratory and clinical practice. Presentations offer practical approaches to applying the human pangenome for genomic interpretation and take on the challenges, standards, and reimbursement barriers surrounding genomic reanalysis, with an additional presentation to be announced.

December 2, 2026 — Session 3: Cancer, Equity, and Global Access. This session addresses where genomic care still falls short and how to close the gap. Presentations share implementation insights on integrated cancer genomic risk assessment and strategies for delivering genomic testing to rare-disease families in low- and middle-income settings, with an additional presentation to be announced.

Overall Learning Objectives

At the conclusion of this activity, participants should be able to:

Describe recent advances in gene therapy and targeted treatments—including CRISPR-based approaches and the expanding therapeutic landscape for skeletal dysplasias—and the collaborative strategies needed to secure patient access to newly approved rare-disease therapies.

Apply emerging diagnostic tools—including pangenome-based genomic interpretation and genomic reanalysis strategies—to improve diagnostic yield and address reimbursement challenges in clinical and laboratory practice.

Discuss approaches for integrating cancer genomic risk assessment into clinical care and for expanding equitable access to genomic testing for rare-disease families in low- and middle-income settings.

Target Audience

This activity is designed for medical geneticists, laboratory geneticists, genetic counselors, genetics trainees and fellows, and other members of the genetics healthcare team involved in the diagnosis, treatment, and management of patients with genetic and genomic conditions.

Topic / Session

Session 1: Novel and Emerging Therapeutics  —  Wednesday, October 7, 2026

Session 2: Smarter Diagnosis  —  Wednesday, November 4, 2026

Session 3: Cancer, Equity, and Global Access  —  Wednesday, December 2, 2026

Andres Morales Corado

Assistant Professor of Pediatrics in the Division of Clinical Genetics at Columbia University Irving Medical Center. A triple board-certified specialist in pediatrics, clinical genetics and genomics, and medical biochemical genetics, his practice and research focus on neurogenetic, skeletal, and inherited metabolic disorders.

John Phillips

David Viskochil
Professor of Pediatrics and clinical geneticist in the Division of Medical Genetics at the University of Utah, where he directs Clinical Genetics Services. His research centers on the molecular genetics of neurofibromatosis type 1 (NF1), and he has led numerous NF1 clinical trials.

Michael Beard

Katherine Bonini
Senior Genetic Counselor and Core Faculty member in the Institute for Genomic Health at the Icahn School of Medicine at Mount Sinai. Her work focuses on the ethical, legal, and social implications of genomic technologies in clinical care, and she has contributed to the Human Pangenome Reference Consortium and other major NIH-funded genomics initiatives.

Melissa Gymrek
Professor at the University of California San Diego, jointly appointed in Computer Science and Engineering and in Medicine. Her lab develops computational tools for analyzing complex genetic variation, including short tandem repeats, and its contribution to human disease.

Eimear Kenny
Professor of Medicine and Genetics and Founding Director of the Institute for Genomic Health at the Icahn School of Medicine at Mount Sinai. She leads research at the intersection of genomics, ancestry, and medicine and is a principal investigator on multiple national genomics consortia, including the Human Pangenome Reference Consortium.

Christian Marshall
Molecular Laboratory Director in the Division of Genome Diagnostics at The Hospital for Sick Children (SickKids) in Toronto and Assistant Professor at the University of Toronto. He oversees clinical next-generation sequencing testing and researches the application of new sequencing technologies to disease diagnosis.

Vaidehi Jobanputra
Chief Diagnostics Officer at the New York Genome Center and Professor of Pathology & Cell Biology at Columbia University Irving Medical Center. She oversees all clinical genomic testing at NYGC and chairs the Medical Genome Initiative steering committee.

Kasia Ellsworth
Senior Director of Clinical Operations at Rady Children's Institute for Genomic Medicine, where she leads the Clinical Genome Center's rapid whole-genome sequencing program for critically ill infants and children.

Holly DeLuca

Noura Abul-Husn
Associate Professor of Medicine and Genetics at the Icahn School of Medicine at Mount Sinai and Vice President of Genomic Health at 23andMe. A physician-scientist board-certified in internal medicine and medical genetics, she focuses on the clinical impact of genetic variation in diverse populations and equitable implementation of genomic medicine.

Ryan Taft
Chief Scientific Officer at Genetic Alliance and Head of Precision Medicine at EspeRare, where he leads global programs expanding access to genomic diagnostics and therapies for rare and undiagnosed diseases. He is the founder of the iHope program, which provides free clinical genome sequencing to underserved patients worldwide.

Accredited Continuing Education Information

AMA PRA Category 1 Credit^TM, ASCLS P.A.C.E.^®

Accreditation

The American College of Medical Genetics and Genomics is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation
The American College of Medical Genetics and Genomics designates this live activity for a maximum of 4.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The American Medical Association (AMA) defines physicians as those individuals who have obtained an MD, DO, or equivalent medical degree from another country.

ASCLS P.A.C.E.® CEU's 

ACMG is approved as a provider of continuing education programs in the clinical laboratory sciences by the American Society for Clinical Laboratory Science (ASCLS) Professional Acknowledgment for Continuing Education (P.A.C.E.®) Program.

ACMG is approved by the Florida Board of Clinical Laboratory Personnel as CE Provider (50-11878). This course is registered with CEBroker # 20-1408008. ACMG is approved by the California Department of Health Services through the ASCLS P.A.C.E.® (275-500-06). This activity has been approved for 0.45 P.A.C.E.® CEU's.

Claiming your Educational Credits

Complete the activity and carefully complete the evaluation form. The deadline to claim educational credits is within 30 days from the date of the activity. Educational credit requests after this date will not be accepted.

Learner Data Consent

ACMG Education reports learner data to respective agency boards and you will be asked for consent during the evaluation process. Your compliance with deadlines and completing evaluations are part of the process in meeting learner needs and ACMG’s education mission.

Technical Support:
You can reach us by email at education@acmg.net or call 301-718-9603.
Support Center Hours: Monday – Friday, 9:00 AM – 5:00 PM Eastern Time.

Fees